---
title: "Taho Pharma submits new drug application to US FDA for apixaban oral dissolving film"
date: "2025-10-01T09:14:16.000Z"
publishedDate: "1 octobre 2025"
summary: "Taho Pharmaceuticals has announced the submission of its new drug application (NDA) to the US Food and Drug Administration (FDA) for TAH3311, apixaban oral dissolving film (ODF). TAH3311 is an innovative formulation designed to improve the delivery of apixaban, a widely used anticoagulant."
importance: ""
sourceUrl: "https://cardiovascularnews.com/taho-pharma-submits-new-drug-application-to-us-fda-for-apixaban-oral-dissolving-film/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2025-10-01-taho-pharma-submits-new-drug-application-to-us-fda-for-apixaban-oral-dissolving-film"
imageUrl: "http://cardiovascularnews.com/wp-content/uploads/sites/14/2016/12/Microscope.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/taho-pharma-submits-new-drug-application-to-us-fda-for-apixaban-oral-dissolving-film/"
---

![Taho Pharma submits new drug application to US FDA for apixaban oral dissolving film](http://cardiovascularnews.com/wp-content/uploads/sites/14/2016/12/Microscope.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/taho-pharma-submits-new-drug-application-to-us-fda-for-apixaban-oral-dissolving-film/*

## L’essentiel

Taho Pharmaceuticals has announced the submission of its new drug application (NDA) to the US Food and Drug Administration (FDA) for TAH3311, apixaban oral dissolving film (ODF). TAH3311 is an innovative formulation designed to improve the delivery of apixaban, a widely used anticoagulant.

## Lien source

https://cardiovascularnews.com/taho-pharma-submits-new-drug-application-to-us-fda-for-apixaban-oral-dissolving-film/
